Trophos SA

Trophos announces results of phase III study of olesoxime in Amyotrophic Lateral Sclerosis

Trophos SA announced the results from the phase III study of Trophos’ lead compound, olesoxime, in 512 patients with ALS. Olesoxime did not demonstrate a significant increase in survival versus placebo in patients receiving riluzole (Rilutek(R)). A trend was seen on patients’ function as me ... more

Trophos announces final patient completion of pivotal phase three efficacy study of olesoxime in Amyotrophic Lateral Sclerosis

Trophos SA announced that the last patient has now completed the major pivotal phase three efficacy study of olesoxime in Amyotrophic Lateral Sclerosis (ALS).Over 500 patients were enrolled in the study and the last patient completed the prescribed study protocol procedures on 15th Septembe ... more

Trophos awarded key US patent covering use of novel cardioprotective compound, TRO40303

Trophos SA announced that the United States Patent and Trademark Office (USPTO) has granted a patent for the use of their novel mitochondrial pore modulator, TRO40303, for cytoprotection. The patent provides coverage for the use of Trophos’ TRO40303 to reduce the cardiac reperfusion injury ... more

Trophos SA

Trophos is a clinical stage pharmaceutical company developing innovative therapeutics for indications with under-served needs in neurology and cardiology. more